1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Abbisko Cayman Limited

Abbisko Cayman Limited

HHKEX:2256
7.04
HKD
-0.50
(-6.70%)
8.63BMarket Cap
Mar 18Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
0.1
- -
0.03
0.79
0.98
- -
Basic EPS, GAAP
-0.19
-1.01
-7.71
-0.8
-0.67
0.04
0.09
- -
Free Cash Flow per Basic Share
-0.12
-0.18
-0.78
-0.59
-0.71
-0.03
0.12
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.65
-1.57
4.04
3.62
3.06
2.93
2.9
2.9
Tangible Book Value per Share
-0.65
-1.57
4.03
3.62
3.05
2.92
2.89
2.89
Basic Weighted Avg Shares
702
702
235
621
647
634
625
648
Sales/Revenue/Turnover
- -
- -
23
- -
19
504
612
- -
Operating Margin (%)
- -
- -
-1,384.97
- -
-2,570.3
-1.67
6.98
- -
Depreciation Expense
8
9
12
16
18
24
22
- -
Net Income, GAAP
-134
-707
-1,810
-496
-432
28
55
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
63.73
52.56
- -
Profit Margin (%)
- -
- -
-7,979.87
- -
-2,264.34
5.62
9.03
- -
Working Capital
282
618
2,508
2,300
1,932
1,885
1,700
1,700
LT Debt
4
- -
45
36
25
13
3
3
Total Equity
-459
-1,105
2,536
2,346
1,981
1,958
1,923
1,923
Return on Invested Capital (%)
- -
- -
- -
- -
- -
-0.15
0.96
- -
Return on Capital (%)
- -
- -
- -
- -
- -
1.44
2.7
- -
Return on Common Equity (%)
- -
- -
- -
-20.3
-19.95
1.44
2.85
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
11
116
300
LT Borrowings
- -
- -
- -
LT Finance Leases
13
11
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
669
660
664
Market Capitalization
2,894
6,160
7,757

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
2,020
2,396
2,127
Cash, Cash Equivalents & STI
1,959
2,332
2,099
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
135
207
427
Payables & Accruals
- -
- -
- -
ST Debt
11
116
300
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-71.1%
-1.81%
Free Cash Flow
- -
-77.8%
-462.96%
Net Income, GAAP
- -
11.85%
95.21%
Sales/Revenue/Turnover
- -
- -
21.45%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
19
2024
- -
- -
504
2025
- -
- -
612

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.67
2024
- -
- -
0.04
2025
- -
- -
0.09

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yao Chang Xu
Full Time Employees
276
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building 3, No. 898 Shanghai SH China 201203
IPO Date
Oct 13, 2021
Website
abbisko.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Abbisko Cayman Limited (2256.HK) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies targeting unmet medical needs in oncology and other therapeutic areas. The company offers a pipeline of small molecule and antibody-drug conjugate (ADC) candidates, including core products such as ABSK011, a selective FGFR3 inhibitor for cholangiocarcinoma and other FGFR3-driven tumors; ABSK012, a next-generation TROP2-targeted ADC for solid tumors; ABSK014, a CDK7 inhibitor for oncology indications; and earlier-stage assets like ABSK003 (SHP2 inhibitor) and ABSK007 (SOS1 inhibitor), all advancing through preclinical and clinical trials. Operations span research and development primarily in China, with headquarters in Cayman Islands and key facilities in Shanghai, China, where the company was founded in 2018. In recent developments, Abbisko has expanded its pipeline through strategic licensing agreements, including partnerships for ADC technologies, and reported positive interim data from Phase I/II trials of ABSK011 in 2024, alongside preparations for multiple Phase II/III initiations; the company also completed a Hong Kong IPO in November 2023 raising approximately HK$1.2 billion to fund late-stage clinical programs and manufacturing scale-up. Abbisko targets global markets with a focus on Asia-Pacific oncology patients, operating through its Shanghai-based subsidiary Abbisko Therapeutics Co., Ltd. and collaborations with international CROs for clinical execution.